WHO raises risk of Ebola outbreak in Congo to 'very high' at national level


Red Cross workers disinfect after handling the body of a person who died of Ebola, as aid agencies intensify efforts to contain a new Ebola outbreak involving the Bundibugyo strain, at the Centre Medical Evangelique (CME) in Hoho commune of Bunia, Ituri province, Democratic Republic of Congo, May 21, 2026. REUTERS/Gradel Muyisa Mumbere

GENEVA, May 22 (Reuters) - The World Health Organization has raised the risk of the Bundibugyo ⁠strain of Ebola turning into a national outbreak in the Democratic Republic of Congo ‌to "very high".

The strain, for which there is no approved vaccine or treatment, was declared an emergency of international concern by the WHO on Sunday.

"We are now revising our risk assessment to very high at the national level, high at the regional ​level, and low at global level," WHO Chief Tedros Adhanom ⁠Ghebreyesus told reporters.

So far, 82 cases have ⁠been confirmed in Congo, with seven confirmed deaths, 177 suspected deaths and almost 750 suspected cases. ⁠The ‌situation in Uganda is stable, with two cases confirmed in people who travelled from the DRC, one of them fatal, Tedros said.

"The potential of this virus spreading rapidly is high, ⁠very high, and that changed the whole dynamic," said Abdirahman Mahamud, ​WHO Director of Health Emergency ‌Alert & Response Operations.

Measures taken in Uganda, including intense contact tracing and cancellation of a ⁠mass gathering, appear ​to have been effective in stemming the spread of the virus, Tedros said.

A U.S. national who was working in Congo has been confirmed to have the virus and been transferred to Germany for care.

"We are also aware ⁠of reports today about another American national with a high-risk ​contact who has been transferred to the Czech Republic," Tedros added.

EXPERIMENTAL DRUG USED FOR CONTACT CASES

The WHO's chief scientist, Sylvie Briand, said an antiviral treatment called Obeldesivir could be used among Ebola contacts to ⁠prevent them from developing the disease.

Obeldesivir is an experimental oral COVID antiviral drug from Gilead Sciences.

"This is a promising treatment drug, but it has still to be implemented under a very, very strict protocol," Briand said.

The WHO said there were early signs of surveillance working as it was picking up ​more cases. However, it was having to catch up as the outbreak ⁠likely started two months ago but was only declared last Friday.

"We are sprinting behind, so that we ​can really try to control this outbreak. Because it (the virus) ‌is still transmitting for the time being, the number ​will keep rising for some time," said WHO’s representative in DRC, Anne Ancia.

(Reporting by Emma Farge and Olivia Le Poidevin; editing by Matthias Williams, Kevin Liffey and Gus Trompiz)

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In World

Swiss widen sanctions against Russia, Belarus in line with EU measures
UK defence show RIAT cancelled because of Iran war
Factbox-Turkey court ruling adds to crackdown on main opposition CHP
Death toll in Honduras ranch shooting rises to at least 20
Rubio cites some progress on Iran talks but "we're not there yet"
Carney stresses importance of Alberta after separation vote announcement
Bangladesh’s rare ‘Donald Trump’ buffalo becomes Eid sensation
Mussolini-themed ads against Meloni spark political row in Italy
Former premier Attal enters race for French president, sparking battle for centrist vote
Volunteers go door-to-door in Congo to tackle Ebola rumors, aid network says

Others Also Read